lege of Management at the
Georgia Institute of Technology. He is an elected fellow of the American
Institute for Medical and Biological Engineering, and is a past Chairman
for the Georgia Biomedical Partnership, a trade association, and is
recipient of the 2004 Biomedical Industry Growth Award for the State of
Georgia. Dr. McNally has a Ph.D. and MSE in Bioengineering from University
of Pennsylvania and an electrical engineering degree (B.E.E.) from
Villanova University.
"Through my years of association with GeoVax, I have become a strong
advocate of the technology developed by Dr. Robinson. During those startup
years, Don Hildebrand, provided the leadership necessary to create a strong
team dedicated to the development of the vaccine and entry into clinical
trials, I welcome this opportunity to join the team to oversee completion
of the trials, and if successful, see worldwide distribution of this
lifesaving vaccine," stated Dr. McNally.
GeoVax is moving forward toward Phase 2 Human Trials.
GeoVax has completed 2 Phase 1 human trials evaluating its HIV/AIDS
vaccines with excellent results and has 3 additional human trials currently
underway. Due to promising results from these 5 trials GeoVax is pushing
forward with plans for critically important and larger Phase 2 human
trials.
GeoVax's HIV/AIDS vaccine is believed to be only the 5th HIV/AIDS
vaccine moving toward Phase 2a human trials conducted by the HVTN. It was
approximately the 65th vaccine protocol evaluated in earlier stage Phase 1
trials.
"We are very pleased that our HIV/AIDS vaccine continues to demonstrate
the promise of not only being safe but potentially effective at eliciting
potentially protective immune responses in humans," stated Dr Harriet
Robinson, Senior Vice President, Research & Development, for GeoVax.
"GeoVax AIDS vaccines have passed the significant hurdles required to
move into Phase 2 trials," stated GeoVax President, Don Hildebrand. Very
few HI
'/>"/>
SOURCE GeoVax Labs, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update2.
U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program3.
Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line4.
China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products5.
VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives6.
Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors7.
New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform8.
Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder9.
Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers10.
AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment11.
SAFC Hitech(TM) Plans Further Expansion Into Asia